Comparison of hemorrhagic effect of heparin and human activated protein C with use of thrombostat 4000

Pathophysiology of Haemostasis and Thrombosis

Volumn 26, Issue 4, 1996, Pages 203-209

  Katsuura, Yasuhiro ^a   Tanabe, Hirofumi ^a   Kiyoki, Mamoru ^a   Funatsu, Akinobu ^b  

^a Pharmacology and Pharmacokinetics Research Department   (Japan)

^b Chemo Sero Therapeutic Research Institute   (Japan)

Author keywords

Activated protein C; Bleeding test; Bleeding time; Heparin; In vitro; Thrombostat 4000

Indexed keywords

ACTIVATED PROTEIN C; FIBRINOGEN; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLEEDING TIME; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; HEMATOCRIT; HEMOSTASIS; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; SHEAR STRESS; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; BLOOD COAGULATION TESTS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; ENZYME ACTIVATION; FIBRINOGEN; HEMATOCRIT; HEMORRHAGE; HEPARIN; HUMANS; INFUSIONS, INTRAVENOUS; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; PROTEIN C; RABBITS;

EID: 0029833973     PISSN: 14248832     EISSN: 14248840     Source Type: Journal    
DOI: 10.1159/000217208     Document Type: Article

References (25)

1. Salzman EW, Deykin D, Shapiro RM, Rosenberg R: Management of heparin therapy. N Engl J Med 1975;292:1046-1050.
2. Hirsh J: Heparin induced bleeding. Nouv Rev Fr Hématol 1984:26: 261-266.
3. Holm HA, Abildgaard U, Kalvenes S: Heparin assays and bleeding complications in treatment of deep venous thrombosis with particular reference to retroperitoneal bleeding. Thromb Haemost 1985,53:278-281.
4. Levine MN, Hirsh J: Hemorrhagic complications of anticoagulant therapy. Semin Thromb Ilemost 1986; 12:39-57.
5. Yamashita T, Matsuoka A, Funatsu A, Yamamoto J: The antithrombotic effect of human activated protein C on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb Res 1994;75:33-40.
6. Katsuura Y, Aoki K, Tanabc F, Kiyoki M, Funatsu A: Characteristic effects of activated human protein C on tissue thromboplastin-induced disseminated intravascular coagulation in rabbits. Thromb Res 1994; 76:353-362.
7. Sakamoto T, Ogawa H, Yasue H, Oda Y, Kitajima S, Tsumoto K, Mi-zokami H: Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. Circulation 1994;90:427-432.
8. Okajima K, Imamura H, Koga S, Inouc M, Takatsuki K, Aoki N: Treatment of patients with disseminated intravascular coagulation by protein C. Am J Hematol 1990;33: 277-278.
9. Esmon CT: Cell mediated events that control blood coagulation and vascular injury. Annu Rev Cell Biol 1993;9:1-26.
10. Messmore HL Jr, Griffin B, Farced J. Coyne E, Seghatchan J: In vitro studies of the interaction of heparin, low' molecular weight heparin and heparinoids with platelets. Ann NY AcadSci 1989;556:217-232.
11. John LCH, Rees GM, Kovacs IB: Effect of heparin on in vitro platelet reactivity in cardiac surgical patients. A comparative assessment by whole blood platelet aggregometry and haemostatometry. Thromb Res 1992;66:649-656.
12. John LCH, Rees GM, Kovacs IB: Inhibition of platelet function by heparin. J Thorac Cardiovasc Surg 1993;105:816-822.
13. Kratzer MAA, Born GVR: Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357-362.
14. Ratnoff OD, Menzie C: New method for determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951;37:316-320.
15. Kristensen J. Eriksson L, Olsson K, Killandcr A, Högman C: Functional capacity of transfused platelets estimated by the Thrombostat 4000/2. EurJ Haematol 1993;51:152-155.
16. Glaser A, Böck M, Rüschermeyer G, Salat C, Heim MU, Hiller E, Mem-pel W: Lagerung von Thrombozytenkonzentraten: Qualitätskontrolle durch In-vitro-Blutungstest. Infu-sionsthcr Transfusionsmed 1993; 20:14-16.
17. Äleskog AE, Killandcr A, Olsson K, Eriksson L, Kristensen J: Preoperative evaluation of primary' hemostasis in patients with thrombocytopenia using the Thrombostat 4000. Semin Thromb Hemost 1995; 21(suppl 2):59-65.
18. Kretschmer V, Huss B, Bonacker G, Hoffmann J. Bewarder S, Weber S, Schulzki T, Koppler H, Heimanns J: Thrombocytopenia-adapted in vitro bleeding test assesses platelet function in thrombocytopenic patients. Semin Thromb Hemost 1995; 21(suppl 2):79-90.
19. Monika WK, Witte M, Budde U, Vigh T, Kretschmer V, Scharrer I: The Thrombostat 4000. A sensitive screening test for von Wiliebrand's disease. Semin Thromb Hemost 1995;21 (suppl 2):44-51.
20. Kretschmer V, Schikor B, Sohngcn D, Dietrich G: In vitro bleeding test-A simple method for the detection of aspirin effects on platelet function. Thromb Res 1989;56:593-602.
21. Kratzer MAA, Negrescu EV, Hirai A, Yco YK, Frank P, Siess W: The Thrombostat system. A useful method to test antiplatelet drugs and diets. Semin Thromb Hemost 1995; 21 (suppl 2):25-31.
22. Ulshofcr B, Dorst V, Kretschmer V, Kohl H, Riedmeller H: Hemostaseo-logical management of urological operations in patients taking aspirin using the Thrombostat 4000. Semin Thromb Hemost 1995;21 (suppl 2): 52-58.
23. Kratzer MAA, Bcllucci S, Caen JP: Detection of abnormal platelet functions with an in vitro model of primary haemostasis. Haemostasis 1985;15:363-370.
24. Sobcl M, McNeill PM, Carison PL, Kermode JC, Adelman B, Conroy R, Marques D: Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991,87:1787-1793.
25. Komoriya K, Inoue K, Takahashi K, Suzuki K: Inhibitory effect of activated protein C on platelet aggregation induced by the prothrombin-converting reaction. Thromb Res 1992;67:705-710.